23 Jul, 2026
According to Straits Research the global fetal bovine serum market size was valued at $1.24 billion in 2025 and is projected to grow from $1.32 billion in 2026 to $2.18 billion by 2034, registering a CAGR of 6.45% during the forecast period (2026–2034).
Fetal bovine Serum (FBS) is the centrifuged fluid component of either clotted or defibrinated whole blood of fetal calves. FBS is a by-product of the beef industry, however its production is dependent on a number of external factors such as weather conditions and changes in beef consumption.
Growth of the Fetal Bovine Serum Market is due to proper concentration use which can fulfill specific metabolic requirements for the cell culture. Furthermore, the market growth is attributed to the use of high content of hormones, carrier proteins and macromolecular proteins in biotechnological research.
Government regulation regarding animal well fare is likely to hamper the market growth. Alternatives to FBS is available in market but it’s not applicable in every media and effectiveness is very low.
Market growth is fueled by rising investments in biotechnology and pharmaceutical research, increasing stem cell applications, expanding biopharmaceutical production, and growing demand for high-quality cell culture media. However, the market faces challenges including limited serum supply and increasing product prices due to rising global demand.
Geographically, the global Fetal Bovine Serums market is segmented into four regions: North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
North America is expected to lead fetal bovine serum market owing to the growing cell based academic research activities regarding fetal bovine serum. Apart from this, growing number of life science research labs, especially in the U.S. is expected to provide a significant boost to the fetal bovine serums market.
Europe is anticipated to gain significant market share in fetal bovine serum market due to the presence of technologically advanced laboratories in the region.
Asia Pacific is expected to be the fastest growing fetal bovine serum market. Increasing academic research activities in region with government and private funding are expected to boost the market growth.
LAMEA is likely to witness sluggish growth in the fetal bovine serum market. Low healthcare expenditure and poor healthcare infrastructure in the region are likely to hamper the market growth.
sales@straitsresearch.com